Gemini is an intelligent digital healthcare company that provides a cloud-based subscription platform for tailoring AI-powered medical modeling and software agent tools to doctors and medical researchers for advanced diagnostics and personalized therapeutics solutions. This may revolutionize clinical medicine.
How can information technologies be applied to automate, personalize and optimize healthcare?
The healthcare industry is undergoing revolutionary transformation because of the convergence of ubiquitous computing and AI combined with genetics, proteomics and bioinformatics.
Most digital healthcare is fragmented and disaggregated, providing critical customer challenges. Existing healthcare services companies merely supply simple static solutions in narrow market niches, such as telehealth or records management. Health care providers are limited to proprietary specialized applications and are forced to stitch together a patchwork of disparate solutions, which is inefficient and frustrating.
Doctors seek integration, automation and personalization of healthcare technologies to encounter useful healthcare solutions, but so far have merely found these to be unmet goals. How can healthcare providers seamlessly organize, manage and optimize health data collection, analysis and utility?
"Gemini" means "twins" and refers to digital twins, a powerful emerging technology that builds models applicable to solving healthcare problems. Gemini supplies a toolkit of advanced technologies in a cloud-based platform to promote personalized medicine. These tools include digital twins modeling for diagnostics and therapeutics, a personal health assistant (autonomous agent), patient relationship management software, data security and specialized partner referrals to provide intelligent patient-centered healthcare solutions. AI, particularly generative AI, empowers our modeling programs, apps and software agents. By automating and unifying these important physician practices, we maximize doctor productivity.
Medical digital twins ("DTs") are likely to become the central – revolutionary – component of the medical industry as it evolves towards personalized medicine, yet are only beginning to develop. DTs enable patient medical information to be collected, analyzed and interrogated in order to identify precise, personalized diagnoses of diseases and to find, develop and computationally test accurate and effective therapies for the patient.
The convergence of AI with personalized medicine is embodied in medical DTs. Much as internet search or the smartphone became strategic technologies, DTs are the single most critical strategic technology in a rapidly developing medical industry. Medicine could consolidate around medical digital models as the most important and indispensable feature. Yet, only Gemini has a concrete vision for the potential of DTs.
The global health market is $12T of which the U.S. health market $4.7T, or $14K per American per year. The digital health industry is segmented but slated to grow from $300B in 2020 to $1.5T in 2030 and the personalized medicine market is expected to grow to $925B in 2030, with 50% U.S. market share.
Our initial customers are physicians, physician groups, hospitals and hospital chains. Eventually, we will target big pharma, biotech companies and medical researchers.
Despite the AI revolution and a growth in digital healthcare ventures, there does not appear to be a competitor in the space for software tools for personalized medicine targeting the market segments of precision diagnostics and therapeutics modeling. Yet, this market is predicted to be very large and fast growth in the next decade as the practice of medicine requires these technologies. Gemini satisfies our customers by providing a la carte services after a basic subscription.
Gemini is founded by prolific inventor Neal Solomon (B.A., Reed College and A.M., University of Chicago), Gemini's chairman and CEO. He holds scores of patents, including, among other technologies, on seminal medical device, bioinformatics, fitness, AI and database technologies. Gemini's seminal technologies are patent pending. We seek $25M in a seed round and are advised by corporate attorneys at Fenwick and West.
After the seed round, Gemini will raise $125M in a Series A round, scheduled to close in 2025 or 2026. The initial capital is primarily for hiring engineers to develop the prototype system and then for initiating a sales program. A Series B round of $300M will fund rapid growth within two years after the Series A round.
Gemini's proprietary technologies solve critical problems in modern medicine. The Gemini platform may become the indispensable digital health toolkit for practicing physicians and biomedical researchers.
Gemini's value proposition is to provide high-quality reasonably-priced solutions to enable physicians to solve patient healthcare challenges. We solve physician problems by integrating SaaS tools for personalized medicine and supplying patient management tools that are superior to alternatives in the healthcare software and consumer healthtech space.
Our aim is to provide our basic medical modeling services to physicians and researchers for under $3 per patient per meeting.
These value propositions reinforce Gemini's compelling business model that consolidates multiple disparate technology and healthcare components. By combining our technologies in an integrated platform, we raise the bar for healthcare management. Our overall value proposition for physicians and patients is to supply technological solutions and high-quality healthcare services at a great value relative to alternatives.
Gemini's diversified business architecture is structured with novel technology applied to several major markets in the following subsidiaries.
Gemini's primary mission is to focus on developing physician tools for personalized (precision) medicine for diagnostics and therapeutics management. Collectively, these tools promote a revolution in intelligent digital healthcare solutions. Gemini assists physicians by supplying digital twins and AI technologies for diagnostics, therapeutics, prognostics and disease management. Gemini focuses on supplying physician tools for solving problems associated with specific patient pathologies. We apply AI and data analytics to build models (digital twins) to optimize precision medicine and therapy management. We also apply patient relationship management software to track patients.
Physicians are licensed to treat patients. GMS is the Gemini subsidiary that provides tools to physicians in order to diagnose and treat disease. GMS develops a digital health platform for doctors that supplies a toolkit of AI empowered technologies including apps, personal healthcare assistants and digital twins for diagnostics and therapeutics. We also supply physicians with patient relationship management and cloud storage technologies. The SaaS platform enables doctors to collect, analyze and track patient data.
A general practitioner (internist) will collect patient health data such as blood and lab tests, IoT device data, genetic tests and imaging data in order to make a diagnosis. A digital healthcare assistant works with a doctor to collect and analyze patient data. A GP will use patient relationship management software and will also employ digital twins modeling technologies to model a patient's pathology and obtain an accurate diagnosis. In some cases, there are different levels of diagnostics. GP's will in some cases also use these technologies to develop therapy options or treatment plans and may work with researchers in GRS.
Specialist physicians and surgeons will work with GP's as well in order to diagnose patient pathologies. Specialists use the GMS platform, including apps, personal healthcare assistants, patient relationship management and digital twins modeling for diagnostics and therapeutics. Various categories of specialists will have access to the GMS platform, but our initial focus will be on the categories of cardiologist, endocrinologist, oncologist, neurologist, orthopedist, gynecologist and pediatrician. Each specialist applies different specialized DT modules that focus on their unique specialty to optimize efficiency.
GMS markets to each of the medical specialty categories. This subsidiary acquires customers via digital marketing, targeted advertising and referrals. The GMS fee structure includes a basic subscription fee plus fees for apps and individual services for personal health assistants and digital twins modeling for diagnostics and therapeutics. For heavy users, we may provide access to third party supercomputers.
GMS offers services across a spectrum of complementary health services.
GES offers medical digital twins services to hospitals, clinics, HMOs and large enterprises.
Gemini Research Solutions (GRS) is focused on supplying tools to biological and medical research institutions, including pharmaceutical companies, biotechnology companies and medical researchers. We apply digital twins modeling technologies and personal health assistants to therapeutics. Our biotechnology clients use our DTs for diagnostics in order to precisely detect the molecular foundations of pathologies. From these analyses, they use our DTs for therapeutic design solutions. Our DTs are also useful for dynamic prognostics in order to track therapeutic applications.
The medical research clients in GRS may work with physicians in GMS. Clinicians may send patients with complex diagnostic challenges to the researchers at GRS, usefully blending basic medicine with clinical medicine. Further, GRS establishes networks of specialized researchers in order to develop a foundation for rapid group solutions to patient disorders; partnership referral services are applied here too.
GRS has three levels of therapeutics that involve our DT modeling system. First, GMS physicians can apply off-the-shelf medicines or biologicals to match a particular generalized pathology. GRS researchers can work with GMS physicians to identify and select the appropriate existing treatment protocol. Second, GRS will design a novel drug for a patient either in medical studies or in conjunction with solutions to GMS patient pathologies. These new drugs are designed in part by working with our DT modeling system for diagnostics and therapeutics. Third, GRS will use the DT modeling system to track drugs in drug testing programs. The DTs will track patient drug candidates in dynamic prognostics in part by applying PRM. Therapeutics becomes a hybrid of clinicians and researchers as both apply AI and the DT modeling system.
Gemini's DT modeling system enables physicians and researchers to see the molecular and cellular mechanisms of individual pathologies. This visualization of disease pathways enables exact therapy targets.
The FDA is far more likely to accelerate drug approvals when our DTs describe the precise molecular pathways and mechanisms of pathology processing. The GRS researcher therapeutics solutions are ideally suited to work with clinical physicians to solve complex medical problems.
GRS is applied to pharmaceutical and biotech company customers.
Gemini Clinical Solutions (GCS) optimized the medical digital twins technologies for drug clinical trials.
The Gemini system is useful for drug clinical trials. The DT modeling system analyzes medication scenario options to select an existing medication for a patient's needs. The drug testing process works with the PRM to sort and track patients in a drug testing study. The PHAs interface with the PRM in order to schedule patient drug tests and follow ups; PHAs also conduct analytics of aggregate patient drug trial data. The PRM sorts patients by eligibility criteria and tracks medical testing on eligible patients with PHAs. A new class of drug is tested in patients with a similar disorder. Each drug option has a different scenario outcome, which is analyzed for each patient. This process assists in the selection of an existing drug.
The DT modeling system is applied to therapy prognostics. The model projects different therapy scenarios based on medical database analyses. The DT model and PHAs analyze a patient pathology and analyze each therapy option with patient health data. The model anticipates an expected drug outcome, while feedback from administration of a drug updates the model.
In an embodiment of the system, physician specialists use the DT modeling system to custom design a novel medication tuned for the patient's unique disease. In effect, the modeling system reverse engineers a solution, viz., novel drug discovery, to correct a genetic mutation or proteomic malformation that presents as a disease. The specialists may use the DT modeling system to design new drugs. A novel drug is tailored to the specific patient proteomic dysfunction. The specialists may design the drug, but they work with a specialized drug company to outsource the novel drug development. The drug company may receive many inquiries from physicians on similar diseases and initiate a doctor cluster network to coordinate a narrow drug study on the novel drug candidate and testing. These parties collaborate using our PRS.
The PRM system connects specialists and the drug company for a custom therapy drug test. The PHAs automate the routine scheduling and collaboration processes with the network of specialists and drug company researchers and administrators. The PRM, PHAs and DT modeling system work together to enable drug companies to build a network of customized drug testing to connect physicians with similarly affected patients. Patient security is integrated into the system to enable some patient anonymized data, yet patient permissions are required for medical data sharing and aggregate data analyses.
The integrated Gemini system views medical therapy as a sort of experimental process that can be automated, tuned and optimized. The initial phases of therapy enable an assessment of limited information as a therapy candidate is introduced. The therapeutic process is akin to completing a puzzle; the DT model obtains more data from diagnostic and medication feedback in order to complete uncertain data. In a sense, without the DT modeling system, doctors and researchers lack the tools to see a precise medical problem and are thus blind to envision a successful therapeutic solution. The therapeutic process requires a constant reassessment of a patient's condition with a new (selected existing or generate a customized) therapy. The DT modeling system supplies a essential way to gain precise molecular data on the fine-grained source of a patient's disease and thereby obtain insight into possible precise therapeutic solutions. With PRM and PHAs, the system builds the DT model, finds the problem, seeks solution options, selects, tests and improves a therapeutic option and, ultimately, manages or eradicates a disease.
GCS is applied to pharmaceutical and biotech company customers.
Gemini Labs performs research into medical digital twins, AI, software agents, data security and health records with biomedical applications to diagnostics, prognostics and therapeutics. We aim to be the world leader in medical modeling.
Our customers consist of two main classes. The first class consists of physicians, physician groups, hospitals and hospital chains. The second class consists of big pharma, biotech companies and university researchers. In the first several years, our focus is on the first group of doctors and hospitals. We plan to go to market with the subsidiaries Gemini Medical Solutions, Gemini Enterprise Solutions, Gemini Research Solutions and Gemini Clinical Solutions as main brands.
In recent years, there has been an economic transformation in the medical profession. While several decades ago, most doctors were solo practitioners, in the last few years a metamorphosis has occurred in which most physicians are part of physician groups, specialist groups, hospitals or HMOs. This model has benefited doctors in the sense that it shifts the burden of administrative load to specialist non-doctor managers, but it also has increased a focus on healthcare efficiency at the expense of the traditional emphasis on building patient relationships and providing patient care.
Interestingly, most doctors don't see themselves as generalists, but rather as a participant in a specific specialty. These specialists are not concerned about the practice of medicine outside of their narrowly specialized sphere. Consequently, we need to consider each category of specialist as a separate field. These include internal medicine, cardiology, endocrinology (esp. obesity and diabetes management), oncology, pulmonology, infectious diseases, gynecology, obstetrics, genetic diseases, gastro-intestinal, orthopedics, allergist, urology, pediatrics, neurology, gerontology, emergency medicine and immunology. These fields represent the main patient healthcare challenges. Each specialty is effectively a distinct market segment.
Unfortunately, most of the practice of medicine is disunified. The existing software model merely automates a patchwork of ancient medical practices that replace manual research and paper record keeping. A great deal of physician time is expended arguing with insurance companies, often by fax or phone, and recording their patient interactions. Much of the medical practice, separate from seeing patients, is time consuming even after considering the administration burden.
From a diagnostic viewpoint, the tools for identifying an accurate diagnosis are sometimes restrictive, insufficient and expensive. Even after finding an initial diagnosis, developing a treatment protocol can involve a process of patient interaction over time to fine tune a therapy with a goal of disease management.
One goal of modern medicine is to automate some of these functions. The effort to transform medical practice to embrace electronic record management has been a step in the right direction. But the general tools for diagnostics, and the haphazard process of diagnostics itself, is inefficient.
With the advent of the genomics revolution, we now have tools to decipher each patient's genome in order to discover a range of genetic dysfunctions. Tools like biomarker analysis also enable more precise identification of diseases. These tools, along with imaging diagnostics, provide a new generation of personalized medicine.
Gemini's SaaS platform supplies a toolkit for physicians that includes modeling software for both diagnostics and therapeutics that integrates with modern genomics and biomarker tools. In addition, Gemini provides GenAI-powered autonomous agents in order to assist physicians with medical research, diagnostics and therapeutics. The PHAs help the physician develop a precise diagnosis and selects a therapy option. Through this process, PRM software assists both physician and patient to track each phase of testing, diagnostics and treatment. PRM (with PHAs) also works with both physician and patient to track the treatment process, including providing treatment feedback such as side effects and drug interactions. Finally, the security software works seamlessly to encrypt data and preserve patient security and privacy. AI empowers each of these functions. All of the Gemini tools work seamlessly to integrate into the physician's practice so as to maximize efficiency of work flow and optimize physician productivity.
The patient is placed in the center of the healthcare process. The system notifies the patient of their position in the process, seeks patient participation (such as in obtaining tests and endeavors to schedule these tests), increases patient personalization, integrates the different biomedical components into a unified system, accelerates the diagnostic and therapeutic processes and maximizes physician transparency.
Investors may request a business plan in order to understand our product development strategy, sales strategy, market projections, recruiting strategy and financial strategy.
Gemini seeks a nine digit investment from institutional investors.
Join physicians and researchers using Gemini to transform patient care through AI-driven digital twins.
Request Access